Wall Street analyst estimates for TransMedics Group, Inc. (TMDX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.29 | ||
| 2026-08-04 | $0.44 | $0.50 | -11.2% |
| 2026-05-05 | $0.30 | $0.62 | -51.6% |
| 2026-02-24 | $0.57 | $0.41 | +39.0% |
| 2025-10-29 | $0.66 | $0.37 | +78.4% |
| 2025-07-30 | $0.92 | $0.48 | +91.7% |
| 2025-05-08 | $0.70 | $0.29 | +141.4% |
| 2025-02-27 | $0.19 | $0.22 | -13.6% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.2M | $7.7M | $13.0M | $23.6M | $25.6M | $30.3M | $93.5M | $241.6M | $441.5M | $605.5M |
| Cost of Revenue | $5.4M | $5.5M | $7.3M | $9.7M | $9.0M | $9.1M | $28.2M | $87.5M | $179.5M | $242.7M |
| Gross Profit | $766,000 | $2.1M | $5.7M | $13.9M | $16.6M | $21.2M | $65.3M | $154.1M | $262.1M | $362.8M |
| Research & Development | $15.6M | $15.0M | $13.7M | $19.9M | $18.8M | $22.3M | $26.8M | $63.3M | $56.0M | $69.1M |
| Selling, General & Admin | $8.1M | $7.6M | $12.3M | $23.6M | $24.2M | $38.3M | $69.9M | $119.6M | $168.6M | $185.2M |
| Operating Expenses | $23.8M | $22.6M | $26.0M | $43.5M | $43.0M | $60.6M | $96.7M | $182.8M | $224.6M | $254.2M |
| Operating Income | -$23.0M | -$20.4M | -$20.2M | -$29.6M | -$26.4M | -$39.4M | -$31.4M | -$28.7M | $37.5M | $108.6M |
| EBITDA | -$22.7M | -$19.1M | -$20.2M | -$27.9M | -$23.2M | -$38.5M | -$29.0M | -$7.7M | $69.9M | $148.5M |
| Interest Expense | $979,000 | $1.1M | $2.4M | $4.4M | $4.0M | $3.9M | $3.7M | $10.8M | $14.4M | $13.8M |
| Pre-tax Income | -$24.1M | -$20.8M | -$23.7M | -$33.5M | -$28.7M | -$44.2M | -$36.2M | -$26.7M | $35.8M | $107.5M |
| Income Tax | 0 | $32,000 | $41,000 | $40,000 | $32,000 | $36,000 | $66,000 | -$1.6M | $316,000 | -$82.8M |
| Net Income | -$24.1M | -$20.8M | -$23.8M | -$33.5M | -$28.7M | -$44.2M | -$36.2M | -$25.0M | $35.5M | $190.3M |
| EPS | $-1.66 | $-1.44 | $-1.23 | $-2.36 | $-1.16 | $-1.60 | $-1.23 | $-0.77 | $1.07 | $5.60 |
| EPS (Diluted) | $-1.66 | $-1.44 | $-1.23 | $-2.36 | $-1.16 | $-1.60 | $-1.23 | $-0.77 | $1.01 | $4.87 |
| Shares Outstanding (Diluted) | $14.5M | $14.5M | $19.2M | $14.2M | $24.7M | $27.6M | $29.6M | $32.5M | $35.2M | $40.5M |
Price
| Price | $82.73 |
| Market Cap | $2.9B |
| Exchange | NASDAQ |
| Country | US |
Related companies: AKRO · BRKR · GKOS · HNGE · IMVT · INDV · KYMR
Explore sector: Healthcare · Medical - Devices
More sections of TMDX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks